Annual Report 2005 - Boehringer Ingelheim

More documents

Recommendations

Info

1 For our people To achieve our corporate objectives we deploy flexible, mobile, self-confident employees prepared to accept responsibility and capable of thinking and acting globally. Our internal principles guide employee selection and assessment. To attain continuous innovation in all we do, we apply our employees’ and managers’ creativity, capability, commitment and willingness to learn and change. The Corporation in this regard delegates responsibilities to employees and acknowledges their success, performance and commitment in meeting agreed goals. Remuneration and classification are based on the task, performance, achievement and competitive comparison. Successfully pursuing our vision, Value through Innovation, calls for the dedication, passion and continuous powers of renewal of our more than 37,000 employees. They are our unique source of strength and inspiration. Our persistent, combined efforts and resulting achievements in pharmaceutical innovation have enabled us to maintain growth and create new jobs. In many countries we have generated a significant volume of employment opportunities, led by the USA, with a total of 1,000 new jobs. The increased employment prospects we offer have been greeted extremely favourably in countries where lowering unemployment is a national challenge. On employment, Boehringer Ingelheim has received numerous accolades. In 2005, we were awarded first price in “Arbeitsplätze absolut” for being the company which generated the highest number of new jobs in Germany. We also gained considerable public recognition in Germany for continuing to increase the number of apprentice- ships which rose from 623 to 698. The relatively Boehringer Ingelheim A n n u A l R e p o R t 2 0 0 5 large number of apprentices in our extensive vocational programmes has won widespread praise as a powerful encouragement to the labour market. Great place to work We are proud of the attractive working environment that we have created and the status that we enjoy as a preferred employer. Authoritative, independent workplace surveys in many countries have confirmed our position among the top companies in this area so vital to recruiting and maintaining high quality employees (see box on page 17, list of awards). Such positive recognition of our company as a great place to work spurs us on to enhance our distinctive company culture still further. Ever responsive to the changing needs of our employees, we at the same time call for everyone to be personally engaged in improving our working environment at the heart of which are mutual respect, fairness, openness and space for both personal and professional development.
Development opportunities Our aspiration to continuously innovate requires firm commitment from everyone in the company. Ongoing dialogue between our employees and their supervisors is also essential to allow all parties to participate in our achievements and development. And our ability to progress coher- ently towards realising our vision by developing and leveraging the immense diversity within the company is pivotal to our success. Our annual employee – supervisor dialogue (Mitarbeitergespraech – MAG) is at the core of our performance and development culture. Engaging and stretching performance objectives are mutually agreed and career aspirations and perspectives for professional development are addressed. Every individual is expected to have a valid and forward-looking development plan to meet the qualification needs of our rapidly changing business and work environment. Career aspirations and prospects are also embed- ded in our global succession planning process. Here we seek to guarantee a strong pipeline of leadership talent for local and international key positions. Talent reviews linked to the succession planning support the identification and development of leadership talent across the corporation. Teamwork is a key element of Boehringer Ingelheim’s corporate culture. In Istanbul, our Turkish employees are here celebrating the 2005 launch of Lead & Learn with its implications for improved teamwork. International assignments are an integrated part of our succession planning process and our business and capability development. Our international assignees represent a large number of our organisations and are uniformly distributed throughout our geographical regions. While the focus groups and purpose of the assignment might differ from strategic positions to development measures or knowledge transfers, these moves serve clearly as a vehicle to enhance cultural understanding and broadening a global mindset. The Boehringer Ingelheim Academy, encompass- ing a variety of development courses and approaches in numerous countries, is designed to support and strengthen our core values and capabilities. Everyone at the company can access local and international development information on our intranets. The Boehringer Ingelheim Academy offers a wide spectrum of options from vocational subjects to leadership development programmes. 00 2004 2003 2002 2001 Personnel costs in millions of EUR 2,671 2,443 2,252 2,175 1,916 Personnel costs as % of net sales 28.0 29.9 30.5 28.7 28.6 Number of employees (incl. apprentices) 37,406 35,529 34,221 31,843 27,980 For our people 1
Page 1 and 2: Value through Innovation Annual Rep
Page 3 and 4: Contents 2 The Shareholders’ Pers
Page 5 and 6: Value through Innovation Our vision
Page 7 and 8: of innovative medications. Our expe
Page 9 and 10: countries since 2000 encourages us
Page 11: Shareholders’ Committee Dr Heribe
Page 14 and 15: 10 Our commitment We have committed
Page 16 and 17: 1 For our neighbours We are fundame
Page 20 and 21: 1 We foster good leadership at all
Page 22 and 23: 1 For our environment In all our ac
Page 24 and 25: 0 Assessments to date show that our
Page 27 and 28: Our R&D drive Holger Pfister has be
Page 29 and 30: New data presented at the 10th Euro
Page 31 and 32: Thanks to new treatments and innova
Page 33 and 34: Laboratory assistants at our Qualit
Page 35 and 36: In addition, our discovery efforts
Page 37 and 38: the age of 65 combined with an agin
Page 39 and 40: Clinical development and registrati
Page 41 and 42: increase the planned patient number
Page 43: Business Development Our Businesses
Page 46 and 47: “spiriva® has obviously improved
Page 48 and 49: Prescription Medicines Boehringer I
Page 50 and 51: Protection around the clock “In t
Page 52 and 53: Stroke treatment and prevention Str
Page 54 and 55: 0 Serotonin and norepinephrine also
Page 56 and 57: Rheumatologic diseases Osteoarthrit
Page 58 and 59: Asia, Australasia, Africa In all ma
Page 60: Consumer Health Care Let’s talk a
Page 63 and 64: Gentle and effective dulcolax® for
Page 65 and 66: health market. With sales of almost
Page 67 and 68: is critical
Page 69 and 70:
at the end of the 1970s with the ma
Page 71 and 72:
Moreover, for Boehringer Ingelheim
Page 73 and 74:
Pioneering college course in biotec
Page 75 and 76:
heartWhen her Labrador Buster fell
Page 77 and 78:
According to the American Veterinar
Page 79 and 80:
Cattle There were two highly gratif
Page 81 and 82:
Group Management Report
Page 83 and 84:
and strength of the group. The grea
Page 85 and 86:
cymbalta®, the anti-depressive in-
Page 87 and 88:
Components of growth in net sales (
Page 89 and 90:
Worldwide growth was achieved by th
Page 91 and 92:
Liquid assets declined by 12 % comp
Page 93 and 94:
Consolidated Financial Statements 2
Page 95 and 96:
C. H. Boehringer Sohn Grundstücksv
Page 97 and 98:
C. H. Boehringer Sohn, Ingelheim Co
Page 99 and 100:
C. H. Boehringer Sohn, Ingelheim St
Page 101 and 102:
The following subsidiaries were exe
Page 103 and 104:
2 Accounting and evaluation methods
Page 105 and 106:
3 Notes to the consolidated balance
Page 107 and 108:
3.3 Financial assets (in millions o
Page 109 and 110:
Pension provisions Boehringer Ingel
Page 111 and 112:
4 Notes to the consolidated profit
Page 113 and 114:
4.7 Holding income (in millions of
Page 115 and 116:
Other mandatory disclosures accordi
Page 117 and 118:
Derivative financial instruments at
Page 119 and 120:
With the following exception, our a
Page 121 and 122:
Product name Active ingredient Indi
Page 123 and 124:
Animal Health Product name Active i
Page 125 and 126:
Comparison of Balance Sheets/ Finan
show all

Annual Report 2005 - Boehringer Ingelheim

Create successful ePaper yourself

Delete template?

Save as template?